To ensure transparency, all participants in ICER meetings, including members of the policy roundtable and any individual giving oral public comment, are required to disclose any potential conflict of interest. All participants must complete a conflict of interest disclosure form prior to the meeting. Participants will be asked during the meeting to verbally restate any potential conflicts they may have.
A potential conflict is defined as a relationship with any health care company (life sciences manufacturer, health plan, health plan association, life sciences manufacturer association, etc.) in the last 12 months. A relationship is defined as you or anyone in your household meeting one or more of the following criteria:
- Receipt or potential receipt of anything of monetary value, including but not limited to, salary or other payments for services such as consulting fees or honoraria in excess of $5,000
- Equity interests such as individual stocks, stock options or other ownership interests in excess of $10,000. Ownership of stock in a mutual fund over which an individual has no trading control does not count toward this item.
- Status or position as an officer, board member, trustee, owner or employee of a health care company, or an organization which receives more than 25% of its funding from health care companies
- Loan or debt interest; or any intellectual property rights such as patents, copyrights and royalties from such rights
- Manufacturer support of research in the clinical area of this meeting in which you are participating (serving as PI for a trial of any of the agents included in this report at any time warrants disclosure).
- Any other relationship that could reasonably be considered a financial conflict of interest
Disclosing a potential conflict does not disqualify a speaker or roundtable member from participating in the meeting.